Organoleptic Agents occupy a significant market segment in the field of pharmaceutical excipients. These agents include a variety of additives used to colour, taste, sweeten, and texturize recipes. EVALUATION OF ORGANOLEPTIC Organoleptic (lit. "impression on the organs") relates to sensory evaluation and encompasses the macroscopic look of the drug, its odour and taste, and, on rare occasions, the sound or snap of its fracture, as well as the drug's feel to touch. Organoleptic agents occupy a significant market segment in the field of pharmaceutical excipients. These agents include a variety of additives used to colour, taste, sweeten, and texturize recipes. These agents have come to play an important role in medicines and cosmetics due to their capacity to promote patient compliance by improving the elegance and aesthetics of a formulation. However, before using them, it is critical to assess their physical and chemical properties, as organoleptic agents, like active pharmaceutical ingredients (APIs), are subject to physical and chemical instability, which leads to deterioration. API-organoleptic drug interaction, exposure to light, air, and oxygen, and changes in pH and temperature can all cause these instabilities. These organoleptic agent instabilities are of great concern because they influence API and formulation stability, potentially leading to API degradation or the manifestation of toxicity. As a result, it is necessary to examine and review the physicochemical qualities of organoleptic agents prior to their application.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia